Search results
Regeneron Reverses On Better-Than-Feared Eylea Sales As Patent Expiration Looms
Investor's Business Daily· 2 days agoRegeneron stock is forming a flat base with a buy point at 998.33, according to MarketSurge. That's...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron...
Mesothelioma
Health· 2 days agoRelated conditions include: Chronic obstructive pulmonary disease (COPD): Affects your breathing ability and blocks airflow Coronary artery disease...
Regeneron Reverses On Better-Than-Feared Eylea Sales
Investor's Business Daily· 2 days agoHigh-dose Eylea came in at $200 million, beating expectations for $189 million, Leerink Partners analyst David Risinger said in a report. The high dose...
Heart doctor relocates office in Pflugerville
Community Impact· 3 days agoThe Cardiovascular Specialists of Texas office in Pflugerville, where Dr. Jerry Gilbert practices, has relocated to a new location in the Stone Hill Town...
FTC Moves to Allow Generic Versions of Ozempic
Futurism via Yahoo Finance· 2 days agoThe Federal Trade Commission is seeking to clear the path for generic Ozempic — but there will be a long road ahead before cheaper versions of the...
Afrezza: Mild to serious side effects and how to manage them
Medical News Today· 2 days agoAfrezza (insulin human) is a brand-name inhaled insulin prescribed to manage blood sugars in adults...
Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 days agoPulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript May 1, 2024 Pulmonx Corporation...
The FTC Strikes Again – Challenging the Listing of 300+ Patents in FDA’s Orange Book | JD Supra
JD Supra· 2 days agoOn April 30, 2024, the FTC issued a press release[1] and warning letters to ten pharmaceutical companies notifying them that the FTC had “availed [themselves] of the FDA’s regulatory process ...
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings Call Trans
Guru Focus· 3 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Regeneron Pharmaceuticals Inc (REGN, Financial) reported a solid start to 2024 with a 7% ...
